Financial Survey: Ginkgo Bioworks (DNA) and Its Rivals

Ginkgo Bioworks (NYSE:DNA) is one of 109 public companies in the “Life Sciences Tools & Services” industry, but how does it weigh in compared to its rivals? We will compare Ginkgo Bioworks to similar companies based on the strength of its valuation, dividends, risk, profitability, earnings, analyst recommendations and institutional ownership.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Ginkgo Bioworks and its rivals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ginkgo Bioworks	2	2	0	0	1.50
Ginkgo Bioworks Competitors	957	3193	5530	179	2.50

Ginkgo Bioworks currently has a consensus price target of $7.00, indicating a potential downside of 27.11%. As a group, “Life Sciences Tools & Services” companies have a potential upside of 0.15%. Given Ginkgo Bioworks’ rivals stronger consensus rating and higher probable upside, analysts clearly believe Ginkgo Bioworks has less favorable growth aspects than its rivals.

Earnings & Valuation

This table compares Ginkgo Bioworks and its rivals gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Ginkgo Bioworks	$170.15 million	-$312.76 million	-2.29
Ginkgo Bioworks Competitors	$2.29 billion	$55.88 billion	-7.60

Ginkgo Bioworks’ rivals have higher revenue and earnings than Ginkgo Bioworks. Ginkgo Bioworks is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Risk & Volatility

Ginkgo Bioworks has a beta of 1.74, indicating that its share price is 74% more volatile than the S&P 500. Comparatively, Ginkgo Bioworks’ rivals have a beta of 0.94, indicating that their average share price is 6% less volatile than the S&P 500.

Institutional & Insider Ownership

78.6% of Ginkgo Bioworks shares are owned by institutional investors. Comparatively, 53.5% of shares of all “Life Sciences Tools & Services” companies are owned by institutional investors. 12.7% of Ginkgo Bioworks shares are owned by insiders. Comparatively, 15.0% of shares of all “Life Sciences Tools & Services” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Ginkgo Bioworks and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Ginkgo Bioworks	-249.20%	-56.97%	-24.60%
Ginkgo Bioworks Competitors	-487.63%	40.45%	-13.30%

Summary

Ginkgo Bioworks rivals beat Ginkgo Bioworks on 9 of the 13 factors compared.

Ginkgo Bioworks Company Profile

Ginkgo Bioworks is a biotechnology company that develops and engineers microorganisms and other cells for use in commercial products. Its platform combines biological research, automation, and software to help customers design, build, and test organisms with desired characteristics. The company provides cell-engineering services and capabilities to organizations in areas including pharmaceuticals, agriculture, food, and industrial chemicals. Its work can include developing and optimizing microbial strains and supporting the production of ingredients and other materials.